Greiner Bio-One
Manufactures high-quality plastic laboratory consumables and life-science products, including 3D cell culture platforms and magnetic 3D bioprinting systems used to generate reproducible spheroids and organoids for drug discovery and biomedical research.
- CEO / Founder
- Sebastian Heiner
- Team Size
- 1001-5000
- Stage
- Subsidiary
Technology & Products
Key Products
Microplates and cell culture vessels; VACUETTE blood collection systems (Preanalytics); 3D cell culture platforms (spheroid/organoid formats); Magnetic 3D bioprinting systems and reagents; Biobanking and sample storage consumables; Sterilization products
Technological Advantage
Greiner Bio-One's advantage rests on its scale and validated consumables portfolio rather than on a proprietary AM process: it supplies standardized microplates, cell culture surfaces and magnetic 3D bioprinting consumables that are widely cited in peer-reviewed bioprinting and 3D cell culture literature (e.g., use of its petri dishes and microplates in published bioprinting studies). The moat is largely brand trust, regulatory/quality compliance and distribution breadth rather than a defensible AM technology patent; the underlying magnetic bioprinting approach is licensed/partnered and replicable by well-resourced competitors such as Corning and Thermo Fisher.
Differentiation
Value Proposition
Standardized, validated labware and 3D cell culture/bioprinting consumables reduce assay-to-assay variability and enable reproducible spheroid/organoid models, lowering researchers' cost-per-experiment and time-to-result versus assembling unvalidated components from multiple vendors.
How They Differentiate
Competes on breadth of validated labware and integrated 3D cell culture/bioprinting consumables rather than on build speed or cost-per-part; differentiated by European manufacturing base, quality/regulatory compliance and a combined Preanalytics + BioScience + Sterilization portfolio, versus Corning and Thermo Fisher's larger single-segment scale.
Market & Competition
Target Customers
Life-science research laboratories, in-vitro diagnostics and clinical labs, pharmaceutical and biotechnology companies, academic and translational research organizations
Industry Verticals
Life Sciences; Medical/Diagnostics; Pharmaceutical; Biotechnology; Research/Academia
Competitors
Corning Incorporated; Thermo Fisher Scientific; Merck KGaA (Sigma-Aldrich)
Growth & Milestones
Growth Metrics
Turnover of €637M with over 2,600 employees across 29 subsidiaries (company profile); 2021 annual sales revenue of €693M; 2017 turnover of €473M with over 2,200 employees.
Major Milestones
1963: Company founded as Greiner Labortechnik (now Greiner Bio-One); 2001: Current international structure emerged from the splitting of Greiner's Labortechnik Division; 2017: Turnover of €473M with over 2,200 employees and 26 subsidiaries; 2023: Celebrated 60th anniversary; 2025: Sebastian Heiner appointed CEO effective December 1, 2025, succeeding Ilke Panzer
Notable Customers
No individually named customers are disclosed, but the new evidence identifies the served customer sectors/end users: pharmaceutical and biotechnology research laboratories, academic and institutional life-science research groups, and clinical/diagnostic healthcare providers (products are described as intended for use by 'properly trained healthcare' personnel and by research labs conducting cell-based and diagnostic assays). Referenced applications include cell proliferation/MTT assays (INTEGRA collaboration), biobanking/cryopreservation (Cryo.s tubes; cited in the Cell Cryopreservation Consumables market alongside Saint-Gobain, Miltenyi Biotec, BioLife Solutions), urinalysis/sample-integrity diagnostics, and clinical biomarker research (e.g., synovial suPAR diagnostics). Geographic presence includes Brazil (Greiner Bio-One in Brazil: Manufacturers' Perspectives), indicating customers across international research and clinical markets.